Despite what we believe is aggressive discounting and downward adjusting of our models based on overly pessimistic probability assumptions, we are still arriving at a target price of $1.00 per share. The current market capitalization is only $2 million. Our target is far more consistent with that we see as a peer-valuation for similar-stage NASDAQ listed companies. We believe several pending catalysts over the next 15 months, including the AMDX sales /spin-off, starting human clinical trials with MANF, reporting results from the eltoprazine Phase IIb data, and the ESS Phase IIa data should allow for the realization of a significantly higher stock price.